More

    UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN  



    [
    UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN  
    [og_img]
    https://www.investing.com/news/press-releases/update-springworks-therapeutics-announces-fda-approval-of-gomekli-mirdametinib-for-the-treatment-of-adult-and-pediatric-patients-with-nf1pn-93CH-3863313


    Investing.com

    Latest articles

    spot_imgspot_img

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here

    spot_imgspot_img